Major histocompatibility complex-directed susceptibility to rheumatoid arthritis

Advances in Immunology

Volumn 68, Issue , 1998, Pages 315-332

  Nepom, Gerald T ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; AUTOIMMUNITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

EID: 0031980319     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (72)

1. Albani, S., Tuckwell, J. E., Esparza, L., Carson, D. A., and Roudier, J. (1992). The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. J. Clin. Invest. 89, 327-331.
2. Auger, I., Escola, J. M., Gorvel, J. P., and Roudier, J. (1996). HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins. Nat. Med. 2, 306-310.
3. Berte, C. C., Tanigaki, N., Tosi, R., Gorski, J., and Mach, B. (1988). Serological recognition of HLA-DR allodeterminant corresponding to DNA sequence involved in gene conversion. lmmunogenetics 27, 167-173.
4. Boki, K. A., Panayi, G. S., Vaughan, R. W., Drosos, A. A., Moutsopoulos, H. M., and Lanchbury, J. S. (1992). HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients, Arthritis Rheum. 37, 749-755.
5. Breedveld, F. C. (1995). New perspectives on treating rheumatoid arthritis. N. Engl. J. Med. 333, 183-184.
6. Calin, A., Elswood, J., and Klouda, P. T. (1989). Destructive arthritis, rheumatoid factor, and HLA-DR4. Arthritis Rheum. 32, 1221-1225.
7. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A. A., Lane, W. S., and Strominger, J. L. (1993). Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178, 27-47.
8. Combe, B., Eliaou, J.-F., Daures, J.-P., Meyer, O., Clot, J., and Sany, J. (1995). Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Rr. J. Rheum. 34, 529-534.
9. Davenport, M. P., Quinn, C. L., Chicz, R. M., Green, B. N., Willis, A. C., Lane, W. S., Bell, J. I., and Hill, A. V. S. (1995). Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DRβ chain. Proc. Natl. Acad. Sci. USA 92, 6567-6571.
10. Davenport, M. P., Godkin, A., Friede, T., Stevanovic, S., Willis, A. C., Hill, A. V. S., and Rammensee, H. G. (1997). A distinctive peptide binding motif for HLA-DRBr0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics 45, 229-232.
11. Demotz, S., Barbey, C., Corradin, G., Amoroso, A., and Lanzavecchia, A. (1996). The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur. J. Immunol. 23, 425-432.
12. Friede, T., Gnau, V., Jung, G., Keilholz, W., Stevanovic, S., and Rammensee, H. G. (1996). Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim. Biophys. Acta 1316, 85-101.
13. Fu, X., Bono, C. P., Woulfe, S. L., Swearingen, C., Summers, N. L., Sinigaglia, F., Sette, A., Schwartz, B. D., and Karr, R. W. (1995). Pocket 4 of the HLA-DR (α, β0401) molecule is a major determinant of T cell recognition of peptide. J. Exp. Med. 181, 915-926.
14. Gao, X., Olsen, N. J., Pincus, T., and Stastny, P. (1990). HLA-DR alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritis. Arthritis Rheum. 33, 939-946.
15. Gaur, L. K., and Nepom, G. T. (1996). Ancestral major histocompatibility complex DRB genes beget conserved patterns of localized polymorphisms. Proc. Natl. Acad. Sci. USA 93, 5380-5383.
16. Gaur, L. K., Nepom, G. T., Snyder, K. E., Anderson, J., Pradarpurkar, M., Yadock, W., and Heise, E. R. (1997). MHC-DRB allelic sequences incorporate distinct intragenic trans-specific segments. Tissue Antigens 49, 342-355.
17. Ghosh, P., Amaya, M., Mellins, E., and Wiley, D. C. (1995). The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462.
18. Gough, A., Faint, J., Salmon, M., Hassell, A., Wordsworth, P., Pilling, D., Birley, A., and Emery, P. (1994). Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum. 37, 1166-1170.
19. Gregersen, P. K., Silver, J., and Winchester, R. J. (1987). The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213.
20. Gyllensten, U. B., Sundvall, M., and Erlich, H. A. (1991). Allelic diversity is generated by intraexon sequence exchange at the DRB1 locus of primates. Proc. Natl. Acad. Sci. USA 88, 3686-3690.
21. Hammer, J., Bono, E., Gallazzi, F., Belunis, C., Nagy, Z., and Sinigaglia, F. (1994). Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180, 2353-2358.
22. Hammer, J., Gallazzi, F., Bono, E., Karr, R. W., Guenot, J., Valsasnini, P., Nagy, Z. A., and Sinigaglia, F. (1995). Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association. J. Exp. Med. 181, 1847-1855.
23. Hiraiwa, A., Yamanaka, K., Kwok, W. W., Mickelson, E. M., Masewicz, S., Hansen, J. A., Radka, S. F., and Nepom, G. T. (1990). Structural requirements for recognition of the HLA-Dwl4 class II epitope: A key HLA determinant associated with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 87, 8051-8055.
24. Kelly, A., and Trowsdale, J. (1994). Novel genes in the human major histocompatibility complex class II region. Int. Arch. Allergy Immunol. 103, 11-15.
25. Kirschmann, D. A., Duffin, K. L., Smith, C. E., Welply, J. K., Howard, S. C., Schwartz, B. D., and Woulfe, S. L. (1995). Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. J. Immunol. 155, 5655-5662.
26. Kraulis, P. J. (1991). MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950.
27. Kwok, W. W., Domeier, M. E., Johnson, M. L., Nepom, G. T., and Koelle, D. M. (1996). HLA-DQB1 codon 57 is critical for peptide binding and recognition. J. Exp. Med. 183, 1253-1258.
28. Lundberg, A. S., and McDevitt, H. O. (1992). Evolution of major histocompatibility complex class II allelic diversity: Direct descent in mice and humans. Proc. Natl. Acad. Sci. USA 89, 6545-6549.
29. Matsushita, S., Takahashi, K., Motoki, M., Komoriya, K., Ikagawa, S., and Nishimura, Y. (1994). Allele specificity of structural requirement for peptides bound to HLA-DRB1°0405 and -DRB1°0406 complexes: Implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J. Exp. Med. 180, 873-883.
30. McDaniel, D. O., Alarcon, G. S., Pratt, P. W., and Reveille, J. D. (1995). Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope). Ann. Intern. Med. 123, 181-187.
31. McNicholl, J. M., Whitworth, W. C., Oftung, F., Fu, X., Shinnick, T., Jensen, P. E., Simon, M., Wohlhueter, R. M., and Karr, R. W. (1995). Structural requirements of peptide and MHC for DR (α, β1°0401) -restricted T cell antigen recognition. J. Immunol. 155, 1951-1963.
32. Miller, G., Nepom, G. T., Reich, M. B., and Thomas, J. W. (1993). Autoreactive T cells from a type I diabetic recognize multiple class II products. Hum. Immunol. 36, 219-226.
33. Moreno, I., Valenzuela, A., Garcia, A., Yelamos, J., Sanchez, B., and Hemanz, W. (1997). Association of the shared epitope with radiological severity of rheumatoid arthritis. J. Rheumatol. 23, 6-9.
34. Nepom, B. S., and Nepom, G. T. (1993). Immunogenetics and the rheumatic diseases. In "Textbook of Rheumatology" (W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, Eds.), 4th ed., Vol. 1, 1, pp. 89-107. Saunders, Philadelphia.
35. Nepom, B. S., Nepom, G. T., Coleman, M., and Kwok, W. W. (1996). Critical contribution of β chain residue 57 in peptide binding ability of both HLA DR and DQ molecules. Proc. Natl. Acad. Sci. USA 93, 7202-7206.
36. Nepom, G. T., and Nepom, B. S. (1992). Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. In "Rheumatic Disease Clinics of North America" (G. T. Nepom, Ed.), Vol. 18, pp. 785-792. Saunders, Philadelphia.
37. Nepom, G. T., Byers, P., Seyfried, C. Healey, L. A., Wilske, K. R., Stage, D., and Nepom, B. S. (1989). HLA genes associated with rheumatoid arthritis. Arthritis Rheum. 32, 15-21.
38. Nepom, G. T., Gersuk, V., and Nepom, B. S. (1996a). Prognostic implications of HLA genotyping in the early assessment of patients with rheumatoid arthritis. J. Rheumatol. 23, 5-9.
39. Nepom, G. T., Ou, D., Lybrand, T., DeWeese, C., Domeier, M., Buckner, J., Mitchell, L. A., and Tingle, A. J. (1996b). Recognition of altered self-MHC molecules modulated by specific peptide interactions. Eur. J. Immunol. 26, 949-952.
40. O'Dell, J. R., Haire, C. E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P. J., Garwood, V., Maloley, P., Klassen, L. W., Wees, S., Klein, H., and Moore, G. F. (1996a). Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291.
41. O'Dell, J., Nepom, B., Haire, C., Drymalski, W., Palmer, W., Eckhoff, J., Klassen, L., Wees, S., Thiele, G., Moore, G., and Nepom, G. T. (1996b). DRB1 typing in rheumatoid arthritis (RA) is useful in predicting response to specific therapy. J. Rheum., in press.
42. Oilier, W., and Thomson, W. (1992). Population genetics of rheumatoid arthritis. In "Rheumatic Disease Clinics of North America" (G. T. Nepom, Ed.), Vol. 18, pp. 741-759. Saunders, Philadelphia.
43. Olsen, N. J., Callahan, L. F., Brooks, R. H., Nance, E. P., Kaye, J. J., Stastny, P., and Pincus, T. (1988). Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am. J. Med, 84, 257-264.
44. Ou, D., Mitchell, L. A., and Tingle, A. J. (1997). HLA-DR restrictive superrypes dominate promiscuous T cell recognition: Association of multiple HLA-DR molecules with susceptibility to autoimmune diseases. J, Rheumatol. 24, 253-261.
45. Penzotti, J. E., Doherty, D., Lybrand, T. P., and Nepom, G. T. (1996). A structural model for TCR recognition of the HLA class II shared epitope sequence implicated in susceptibility to rheumatoid arthritis. J. Autoimmun. 9, 287-293.
46. Penzotti, J. E., Nepom, G. T., and Lybrand, T. P. (1997). TCR/HLA-DRB1°04 molecular modeling predicts site-specific interactions for the DR shared epitope associated with rheumatoid arthritis. Arthritis Rheum. 40, 1316-1325.
47. Ragoussis, J., Monaco, A., Mockridge, I., Kendall, E., Campbell, R. D., and Trowsdale, J. (1991). Cloning of the HLA class II region in yeast artificial chromosomes. Proc. Natl. Acad. Sci. USA 88, 3753-3757.
48. Rammensee, H. G., Friede, T., and Stevanoviic, S. (1995). MHC ligands and peptide motifs: First listing, Immunogenetics 41, 178-228.
49. Reveille, J. D., Alarcon, G. S., Fowler, S. E., Pillemer, S. R., Neuner, R., Clegg, D. O., Mikhail, I. S., Trentham, D. E., Leisen, J. C. C., Gluhm, G., Cooper, S. M., Duncan, H., Tuttleman, M., Heyse, S. P., Sharp, J. T., and Tilley, B. (1996). HLA-DRB1 genes and disease severity in rheumatoid arthritis. Arthritis Rheum. 39, 1802-1807.
50. Ronningen, K. A., Spurkland, A., Egeland, T., Iwe, T., Munthe, E., Vartdal, E., and Thorsby, E. (1990). Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74. Tissue Antigens 36, 235-240.
51. Rothbard, J. B., Marshall, K., Wilson, K. J., Fugger, L., and Zaller, D. (1994). Prediction of peptide affinity to HLA DRB1°0401. Int. Arch. Allergy Immunol. 105, 1-7.
52. Roudier, J., Petersen, J., Rhodes, G. H., Luka, J., and Carson, D. A. (1989). Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR β-1 chain and the Epstein-Barr virus glycoprotein gpl10. Proc. Natl. Acad. Sci. USA 86, 5104-5108.
53. Salvat, S., Auger, I., Rochelle, L., Begovich, A., Geburher, L., Sette, A., and Roudier, J. (1994). Tolerance to a self-peptide from the third hypervariable region of HLA DRB1°0401 in rheumatoid arthritis patients and normal subjects. J. Immunol. 153, 5321-5329.
54. Sette, A., Sidney, J., Oseroff, C., del Guercio, M., Southwood, S., Arrhenius, T., Powell, M. F., Colon, S. M., Gaeta, F. C. A., and Grey, H. M. (1993). HLA-DR4Dw4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151, 3163-3170.
55. Sigurdardottir, S., Borsch, C., Gustafsson, K., and Andersson, L. (1992). Exon encoding the antigen-binding site of MHC class II β-chains is divided into two subregions with different evolutionary histories. J Immunol. 148, 968-973.
56. Starkebaum, G., Loughran, T. P., Jr., Gaur, L. K., Davis, P., and Nepom, B. S. (1997). Immunogenetic similarities between patients with Felty's Syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 40, 624-626.
57. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1994). Crystal structure of the human class II MHC protein HLA-DR1 Complexed with an influenza virus peptide. Nature, 368, 215-221.
58. Thomas, R., and Lipsky, P. E. (1996). Presentation of self peptides by dendritic cells: Possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 39, 183-190.
59. Tugwell, P., Pincus, T., Yocum, D., Stein, M., Gluck, O., Kraag, G., McKendry, R., Tesser, J., Baker, P., and Wells, G., for the Methotrexate-Cyclosporine Combination Study Group (1995). Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N. Engl. J. Med. 333, 137-141.
60. van Zeben, D., Hazes, J. M. W., Zwindcrman, A. H., Cats, A., Schreuder, G. M. T., D'Amaro, J., and Breedveld, F. C. (1991). Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Arthritis Rheum. 34, 822-830.
61. Vehe, R. K., Nepom, G. T., Wilske, K. R., Healey, L. A., Stage, D., Begovich, A. B., and Nepom, B. S. (1993). Erosive rheumatoid factor positive and negative rheumatoid arthritis are immunogenetically similar. J. Rheumatol. 21, 194-196.
62. Wagner, U., Kaltenhauser, S., Sauer, H., Arnold, S., Seidel, W., Hantzschel, H., Kalden, J. R., and Wassmuth, R. (1997). HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum. 40, 341-351.
63. Weyand, C. M., Hicok, K. C., Conn, D. L., and Goronzy, J. J. (1992). The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann. Intern. Med. 117, 801-806.
64. Weyand, C. M., McCarthy, T. G., and Goronzy, J. J. (1995). Correlations between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J. Clin. Invest. 95, 2120-2126.
65. Willkens, R. F., Nepom, G. T., Marks, C. R., Nettles, J. W., and Nepom, B. S. (1991). The association of HLA-Dwl6 with rheumatoid arthritis in Yakima Indians: Further evidence for the "shared epitope" hypothesis. Arthritis Rheum, 34, 43-47.
66. Wilske, K. R., and Yocum, D. E. (1996). RA: The status and future of combination therapy. J. Rheumatol. 23, 1.
67. Wordsworth, B., Lanehbury, J. S. S., Sakkas, L. I., Welsh, K. I., Panayi, G. S., and Bell, J. I. (1989). HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc. Natl. Acad. Sci. USA 86, 10049-10053.
68. Wordsworth, P., Pile, K. D., Buckley, J. D., Lanehbury, J. S. S., Oilier, B., Lathrop, M., and Bell, J. I. (1992). HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am. J. Hum. Genet. 51, 585-591.
69. Woulfe, S. L., Bono, C. P., Zacheis, M. L., Kirschmann, D. A., Baudino, T. A., Swearingen, C., Karr, R. W., and Schwartz, B. D. (199.5). Negatively charged residues interacting with the p4 pocket confer binding specificity to DRBI°0401. Arthritis Rheum. 38, 1744-1753.
70. Zanelli, E., Gonzalez-Gay, M. A., and David, C. S. (1995), Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol. Today 16, 274-278.
71. Zanelli, E., Krco, C. J., Baisch, J. M., Cheng, S., and David, C. S, (1996). Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 93, 1814-1819.
72. Zanelli, E., Krco, C. J., and David, C. S. (1997). Critical residues on HLA-DRB1°0402 HV3 peptide for HLA-DQ8-restricted immunogenicity. Implications for rheumatoid arthritis predisposition. J. Immunol. 158, 3545-3551.